Prospects for human papillomavirus vaccine development: Emerging HPV vaccines

Current Opinion in Obstetrics and Gynecology

Volumn 10, Issue 1, 1998, Pages 15-19

  Hines, Jeffrey F ^a,c   Ghim, Shin Je ^b   Jenson, A Bennett ^b  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c Division of Gynecologic Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAPILLOMA VIRUS VACCINE; PROTEIN P53; UNCLASSIFIED DRUG; VIRUS VACCINE;

CELLULAR IMMUNITY; CLINICAL TRIAL; CONDYLOMA; FEMALE; GENE TRANSFER; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CARCINOMA; UTERINE CERVIX DYSPLASIA; VACCINE PRODUCTION; VIRUS CARCINOGENESIS; VIRUS GENE; VIRUS PARTICLE; WART VIRUS;

EID: 0031912896     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-199802000-00004     Document Type: Review

References (32)

1. DiMaio D. Transforming activity of bovine and human papillomaviruses in cultured cells. Adv Cancer Res 1991; 56:133-159.
2. Sherr C. Mammalian G1 cyclins. Cell 1993; 73:1059-1065.
3. Weinberg R. The retinoblastoma protein and cell cycle control. Cell 1995; 81:323-330.
4. Lane D. Cancer: p53, guardian of the genome. Nature 1992; 358:15-16.
5. Broker T. Structure and genetic expression of papillomaviruses. Obstet Gynecol Clin North Am 1987; 14:329-348.
6. Bosch F, Manos M, Munoz N, Sherman M, Jansen A, Peto J. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995; 87:796-802.
7. Lorincz A, Reid R, Jenson A, Greenberg M, Lancaster W, Kurman R. Human papillomavirus infection of the cervix: relative risk of 15 common anogenital types. Obstet Gynecol 1992; 79:328-337.
8. Hines J, Ghim S, Christensen N, Kreider J, Barnes W, Schlegel R, Jenson A. Role of conformation epitopes expressed by human papillomavirus major capsid proteins in the serologic detection of infection and prophylactic vaccination. Gynecol Oncol 1994; 55: 13-20.
9. Hines J, Ghim S, Christensen N, Kreider J, Barnes W, Schlegel R, Jenson A. The expressed L1 proteins of HPV-1, HPV-6, and HPV-11 display type-specific epitopes with native conformation and reactivity with neutralizing and non-neutralizing antibodies. Pathobiology 1994; 62:165-171.
10. Kirnbauer R, Booy F, Cheng N, Lowy D, Schiller J. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992; 89:12180-12184.
11. Sasagawa T, Pushko P, Steers G, Gschmeissner S, Hajibagheri M, Finch J, et al. Synthesis and assembly of virus-like particles of human papillomavirus type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology 1995; 206:126-135.
12. Zhou J, Sun X, Stenzel D, Fraser I. Expression of vaccinia recombinant HPV-16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. J Virol 1991; 185:251-257.
13. Schiller J, Roden R. Papillomavirus-like particles. Papillomavirus Rep 1995; 6:121-128.
14. Nardelli-Haefliger D, Roden R, Benyacoub J, Sahli R, Kraehenbuhl J, Schiller J, et al. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun 1997; 65:3328-3336.
15. Dupuy C, Buzoni-Gatel D, Touze A, Cann P, Bout D, Coursaget P. Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles. Microb Pathogen 1997; 22:219-225. Data are presented which demonstrate that VLPs induce cellular immunity in addition to previously described humoral immunity.
16. Luxton J, Rose R, Coletart T, Wilson P, Shepherd P. Serological and T-helper cell responses to human papillomavirus type 16 L1 in women with cervical dysplasia or cervical carcinoma and in healthy controls. J Gen Virol 1997; 78:917-923. Again, data are presented which demonstrate that VLPs induce cellular immunity in addition to previously described humoral immunity.
17. Roden R, Hubbert N, Kirnbauer R, Christensen N, Lowy D, Schiller J. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol 1996; 70:3298-3301. HAI is a simple assay that can monitor conformation-dependent and type-specific reactivity in individuals immunized with multiple HPV types.
18. Roden R, Greenstone H, Kirnbauer R, Booy F, Jessie J, Lowy D, Schiller J. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol 1996; 70:5875-5883. HPV pseudotypes may facilitate the analysis of papillomavirus assembly, infectivity and serologic relatedness.
19. Suzich J, Ghim S, Palmer-Hill F, White W, Tamura J, Bell J, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995; 92:11553-11557.
20. Breitburd F, Kirnbauer R, Hubbert N, Nonenmacher B, Trin-Dinh-Desmarquet C, Orth G. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69:3959-3963.
21. Kirnbauer R, Chandrachud L, O'Neil B, Wagner E, Grindlay G, Armstrong A, et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 1996; 219:37-44. Animal model demonstrating the effectiveness of VLPs as immunogens for prophylactic vaccination.
22. Yamada T, Manos M, Peto J, Greer C, Munoz N, Bosch F, Wheeler C. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol 1997; 71:2463-2472. This study evaluates variation of DNA in HPV-16. Variants may prove to be important for the determination of risk of dysplasia and cancer development and the design of vaccine strategies.
23. Wu T, Kurman R. Analysis of cytokine profiles in patients with human papillomavirus-associated neoplasms. J Natl Cancer Inst 1997; 89:185-187. A comprehensive review of cytokines associated with HPV-mediated diseases.
24. Feltkamp M, Smits H, Vierboom M. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23:2242-2249.
25. Alexander M, Salgaller M, Celis E, Sette A, Barnes W, Rosenberg S, Steller M. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. Am J Obstet Gynecol 1996; 175:1586-1593.
26. Krul M, Tijhaar E, Kleijne J, Van Loon A, Nievers M, Schipper H, et al. Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant Salmonella strains. Cancer Immunol Immunother 1996; 43:44-48.
27. Boursnell M, Rutherford E, Hickling J, Rollinson E, Munro A, Rolley N, et al. Construction and characterization of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 1996; 14:1485-1494.
28. Borysiewicz L, Fiander A, Nimako M, Wilkinson G, Westmoreland D, Evans A, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996; 347:1523-1527. Phase I/II trial of E6/E7 proteins as immunotherapy in patients with advanced cervical carcinoma. One patient of eight had a demonstrable effector CTL response. Additional studies are warranted to evaluate this strategy further.
29. Beer-Romero P, Glass S, Rolfe M. Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells. Oncogene 1997; 14:595-602. Antisense targeting of E6AP increased p53 levels and inhibited cell growth. Further investigation is warranted to evaluate the therapeutic potential of this strategy of gene therapy.
30. Hamada K, Alemany R, Zhang W, Hittelman N, Lotan R, Roth J, Mitchell M. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res 1996; 56:3047-3054. Transfection of cervical carcinoma cells with wild-type p53 via an adenoviral vector caused increased p53 expression and suppressed cell growth. Further investigation is warranted to evaluate the therapeutic potential of this strategy of gene therapy.
31. Hamada K, Sakaue M, Alemany R, Zhang W, Horio Y, Roth J, Mitchell M. Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells. Gynecol Oncol 1996; 63:219-227. Transfection of cervical carcinoma cells with E6/E7 antisense RNA via an adenoviral vector suppressed cell growth. Further investigation is warranted to evaluate the therapeutic potential of this strategy of gene therapy.
32. Madrigal M, Janicek M, Sevin B, Perras J, Estape R, Penalver M, Averette H. In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma. Gynecol Oncol 1997; 64:18-25. In vitro oligonucleotide targeting of start codon sequences of HPV-16 E6/E7 caused suppression of cell growth. Further investigation is warranted to evaluate the therapeutic potential of this strategy of antigene therapy.